作者感谢生物信息学解决方案公司的乔纳森·克里格博士为具有代表性的实验操作质谱仪，以及盖德斯-麦卡利斯特小组的成员在实验设置和手稿反馈方面给予的帮助。作者承认部分资金支持 来自班廷研究基金会-贾里斯洛夫斯基奖学金发现奖，新前沿研究基金-探索（NFRFE-2019-00425），加拿大创新基金会（JELF 38798）为J.G.M，以及NSERC加拿大研究生奖学金-硕士和安大略研究生奖学金的B.B，和女王伊丽莎白二世研究生奖学金为A.S.。

圭尔夫大学动物利用议定书4193批准的以下议定书使用了源自BALB/c小鼠的永生巨噬细胞系。值得注意的是，其他小鼠菌株或其他永生细胞来源可以应用于概述的协议，并有足够的测试，以优化详细的参数。以下协议将导航从大噬细胞的冷冻小瓶开始的步骤。细胞储存在10%FBS（胎儿牛血清），1%L-谷氨酰胺和5%笔/链球菌（青霉素-链霉素）混合物DMEM（杜尔贝科的改性鹰介质）和20%DMSO（二甲基硫氧化物）。
1. 培养 C.新福尔曼
<ol><li>使用甘油股票， 条纹野生类型 C. 新福尔曼菌 株 （H99） 到酵母提取肽德克斯特罗斯 （YPD） 藻类板分离单个殖民地.</li>
	<li>在静态孵化器中，在37°C下孵化16小时。</li>
	<li>在松散封顶的 10 mL 试管中，在 5 mL 的 YPD 汤中选择一个野生类型 C. 新福尔曼 菌株和文化的单一殖民地。以四倍为下执行。</li>
	<li>在 200 rpm 的摇晃孵化器中，在 37 °C 下过夜 16 小时。</li>
	<li>第二天亚文化每个通宵文化在1:100稀释成3 mL YPD汤。</li>
	<li>测量真菌培养的光学密度 （OD600nm）值，以确定中日志阶段。根据光谱仪 ，C. neoformans 野生型菌株在 YPD 中通常经过 6 到 8 小时的孵化后达到中日志阶段，一般 OD600nm 值在 1.0 到 1.5 之间。</li>
	<li>一旦细胞达到中日志阶段，将10 μL真菌细胞悬浮液放入清洁的1.5 mL微中心管中，在无菌的1x磷酸盐缓冲盐水中稀释1:100。使用血细胞计计算细胞数量。</li>
</ol>2. 培养巨噬细胞
注:确保工作环境在细胞培养工作之前进行消毒。
<ol><li>细胞培养介质的制备<ol>
<li>抗生素补充介质:加入10%FBS（胎儿牛血清），1%L-谷氨酰胺和5%笔/链球菌（青霉素-链霉素）混合物到DMEM（杜尔贝科的改性鹰介质）。通过 0.2 μm 完整滤镜系统过滤介质，并在 4 °C 下存储。</li>
		<li>无抗生素介质:遵循相同的协议，但省略笔/链球菌混合物。</li>
	</ol></li>
	<li>播种巨噬细胞 注:抗生素补充介质（2.1.1.）应在细胞培养工作之前加热至37°C。<ol>
<li>在37°C珠浴中快速解冻大噬细胞小瓶。</li>
		<li>通过在1mL抗生素补充介质中重新悬生细胞来清洗冷冻溶液的细胞。 注意:需要额外的预防措施，以确保细胞不会因为苛刻的管道而解洗。</li>
		<li>将重新悬念的细胞转移到无菌的15mL管中。</li>
		<li>在室温下以400× 克 离心5分钟，将颗粒细胞离心。</li>
		<li>用血清移液器或真空吸气器小心地去除超纳坦。</li>
		<li>在10 mL抗生素补充介质中轻轻重新悬生颗粒。</li>
		<li>轻轻移液器将细胞重新悬停在 60 x 15 mm 细胞培养处理的盘子中。</li>
		<li>在37°C下孵化菜肴，隔夜 含5%二氧化碳。</li>
	</ol></li>
	<li>巨噬细胞的初始通过 注:冷冻细胞库存通常每瓶含有500万至1000万个细胞（约1 mL）。第二天，在播种协议中幸存下来的巨噬细胞将粘附在细胞培养皿的底部，并准备通过。<ol>
<li>在细胞培养工作之前，加热抗生素补充介质（步骤2.1.1）至37°C。确保在细胞培养工作之前对工作环境进行消毒。使用光显微镜可视化细胞，以确保细胞的粘附和健康。</li>
		<li>用血清移液器或真空吸气器从盘子中取出细胞培养介质。</li>
		<li>轻轻将 5-7 mL 的无菌室温 PBS（磷酸盐缓冲盐水）添加到 60 x 15 mm 盘中。</li>
		<li>轻轻倾斜盘洗粘性细胞。</li>
		<li>使用血清学移液器或真空吸气器取出 PBS。</li>
		<li>将 1 mL 的冷 PBS（储存在 4 °C）添加到细胞中，倾斜盘将 PBS 分布在所有细胞上，并允许在室温下坐 1 分钟。</li>
		<li>通过轻轻敲击盘、将冷 PBS 吹到细胞上或使用细胞刮刀来释放细胞。</li>
		<li>在菜中加入 9 mL 的抗生素补充介质。</li>
		<li>在一个新的60×15毫米菜，添加9 mL的新鲜抗生素补充介质和1 mL的重新悬生细胞从原来的菜。</li>
		<li>一旦需要的通过板的数量被填充，从原来的菜的重新悬息细胞可以丢弃。</li>
		<li>在上述设置（步骤 2.2.8）中孵育新菜。</li>
		<li>当细胞达到 70-80% 的汇合时（大约每 2 天根据所使用的细胞系和介质执行后续传递）。 注:在感染实验之前，应至少通过五次巨噬细胞。根据细胞系的不同，感染实验应通过 25 到 30 个通道进行。在25到30个通道后，细胞应冻结或丢弃。第 2.4 节或第 2.5 节可以根据实验计划进行选择。第2.4节将用于以下部分。</li>
	</ol></li>
	<li>感染前播种大噬细胞<ol>
<li>执行传递协议步骤 2.3.1 到 2.3.7。</li>
		<li>使用血细胞计或自动细胞计数器确定细胞密度（细胞/mL）。</li>
		<li>将 0.3 x 106 微噬细胞转移到 6 井细胞培养板的单井中。</li>
		<li>使用抗生素补充介质（步骤 2.1.1）将井的总体积调整到 1 mL。</li>
		<li>重复步骤 2.4.3 和 2.4.4，直到 8 口油井被填充（4 口井填充在两个单独的板中）。</li>
		<li>可选地，在剩余的两口井中填充 1 mL 的室温 PBS，以在孵化期间保持水分水平。</li>
		<li>允许细胞在感染前2.2.8步2d的潜伏条件下生长。</li>
	</ol></li>
	<li>感染当天播种大噬细胞<ol>
<li>执行传递协议步骤 2.3.1 到 2.3.7。</li>
		<li>使用血细胞计或自动细胞计数器确定细胞密度（细胞/mL）。</li>
		<li>种子 1.2 x 106 巨噬细胞进入 6 井细胞培养板的单井。</li>
		<li>使用抗生素补充介质（2.1.1）将井的总体积调整到1 mL。</li>
		<li>重复 2.4.3 和 2.4.4，直到 8 口井被填充（4 口井填充在两个单独的板中）。</li>
		<li>可选地，在剩余的两口井中填充 1 mL 的室温 PBS，以在孵化期间保持水分水平。</li>
		<li>在步骤 2.2.8 中提及的 3 小时条件下孵化细胞，使细胞能够粘附在井上。</li>
	</ol></li>
</ol>3. 与C.新福尔曼的巨噬细胞感染
注:达到70-80%汇合后，每口井将有大约1.2 x 106 个巨噬细胞。要达到所需的100:1感染（MOI）的多重性，每个反应需要1.2 x 108 真菌细胞。文化必须在生物四倍体中相应地设置。
免责声明:100:1 的 MOI 在我们的研究组中取得了理想的成果，旨在向读者提供建议。对于更具传染性的 C. 新福尔曼 菌株或弹性较小的巨噬细胞系，可能需要较低的 MOI。感染验证（第3.5节）可用于确定特定 C.新福尔曼- 巨噬细胞组合的理想MOI。
<ol><li>真菌细胞的制备<ol>
<li>跟随第 1 步， 将 C. 新福尔曼人 增长到中日志阶段。</li>
		<li>收集和离心电池在1，500 x g 10分钟，轻轻洗颗粒与无菌室温PBS，并重复共三次洗涤。</li>
		<li>无抗生素细胞培养介质（步骤2.1.2）中的再悬生细胞，达到1.2 x 108 细胞/mL的浓度。</li>
	</ol>
</li>
	<li>大噬细胞的制备<ol>
<li>可视化 6 井板中的每口井，以确保细胞达到 70-80% 的汇合度。或者，可以测量细胞，以达到每口井约1.2×106 大噬细胞。</li>
		<li>按照步骤 2.3.1 到 2.3.4。</li>
	</ol>
</li>
	<li>C.新福尔曼和巨噬细胞的共同培养<ol>
<li>将重新悬念的 C.新福尔曼细胞 （步骤3.1.3）的1 mL添加到包含第3.2节中制备的巨噬细胞的4口井中。 注:在开始实验之前，需要计算所需的板数。在空井中加入 1 mL 的无抗生素介质（步骤 2.1.2）。</li>
		<li>允许细胞在列出的条件下孵育（步骤 2.2.8），持续 3 小时。</li>
		<li>使用血清学移液器或真空吸气器从盘子中取出细胞培养介质。</li>
		<li>轻轻添加 1 mL 的无菌室温 PBS。</li>
		<li>轻轻倾斜板洗非附着或非噬细胞外 C.新福尔曼细胞 。</li>
		<li>使用血清移液器或真空吸气器取出 PBS，重复共洗三次。重复 3.3.4 到 3.3.5 两次。</li>
	</ol>
</li>
	<li>未受感染的巨噬细胞<ol>
<li>同样，使用 6 井板的 4 口井作为仅限巨噬细胞的样品。在这些油井中加入1 mL的无抗生素介质（步骤2.1.2）。</li>
		<li>重复步骤 3.3.2 到 3.3.6。</li>
	</ol>
</li>
	<li>感染验证 注:使用细胞毒性检测，可以测量感染能力。以下协议将突出显示细胞毒性产品的应用，以测量 LDH（乳酸脱水酶）释放。其他细胞毒性产品也可用于。<ol>
<li>大噬细胞 C.新福尔曼感染 的准备<ol>
<li>重复步骤 1、2 和 3（最多 3.5）。如果愿意，LDH 检测可以分三次进行。</li>
			<li>继步骤 3.3.6 后，在 6 井板中每个井中添加 1 mL 的无抗生素介质 （2.1.2）。</li>
			<li>重复步骤 2.4.3 和 2.4.4，直到已填充 3 口井加 3n 口井（其中 n 是测量的时间点数）。</li>
			<li>在步骤 2.2.8 列出的条件下孵化细胞。</li>
			<li>在选定的时间点（例如，1、3、6、12 和 24 小时）收集超标剂，根据制造商的说明测量 LDH 释放</li>
			<li>同时，未受感染的巨噬细胞将被分析为最大细胞毒性的确定值。</li>
			<li>计算细胞毒性如下: <img alt="Equation 1" src="/files/ftp_upload/61881/61881equ01.jpg">
</li>
		</ol>
</li>
	</ol>
</li>
</ol>4. 样本收集
<ol><li>共同文化和未受感染的宏噬菌体收藏<ol>
<li>在细胞中加入1 mL的冷PBS（从3.3.6和3.4.2），并允许在室温下坐1分钟。</li>
		<li>通过轻轻敲击板或轻轻吹动冷 PBS 对细胞释放板中的细胞。 注意:应避免使用细胞刮刀，因为这可能导致细胞裂解。</li>
		<li>移液器将细胞重新插入15mL管中。</li>
		<li>离心机细胞在室温下在400 x g 下5分钟，并去除超纳坦。</li>
		<li>加工细胞（详见第 5 步）立即或闪烁冻结在液氮中，并储存在 -80 °C 以供以后处理。</li>
	</ol>
</li>
</ol>5. 细胞蛋白质组
注:必须针对所分析的细胞类型优化足够的裂解（即周期和振幅的数量取决于细胞颗粒大小和探针声波模型的功率百分比）。
<ol><li>受感染的巨噬细胞裂解<ol>
<li>100 mTris-HCl （pH 8.5） 的 300 μL 中重新悬生颗粒细胞（步骤 4.1.5），由新鲜溶解的蛋白酶抑制剂鸡尾酒片组成。 注:在开始实验之前，在10mL的冰冷100mTris-HCl（pH 8.5）中加入一种蛋白酶抑制剂鸡尾酒片剂。</li>
		<li>在冰浴中探测声波细胞15个周期，30个开启和30个关闭，以解冻细胞。</li>
		<li>离心机细胞在400 x g下短暂地为30s，小心不要形成颗粒，只是为了去除管子两侧的液体，然后将样品转移到2mL Lo-bind微中心管中。</li>
		<li>将 20% SDS 的 1:10 体积添加到 2% 的最终浓度中。</li>
		<li>将 1:100 体积的 1 M 二甲二醇 （DTT） 添加到 10 mM 的最终浓度中，并通过管道彻底混合样品，然后在 95 °C 的热加热块上孵育 10 分钟，在 800 rpm 搅拌时进行。接下来，冷却到室温（冰上可以冷却）。</li>
		<li>添加 1:10 体积 0.55 M 碘乙酰胺 （IAA）， 获得 55 mM 的最终浓度，并通过管道彻底混合样品。在室温下在黑暗中孵育20分钟。</li>
		<li>加入100%丙酮，获得80%丙酮的最终浓度，并在-20°C过夜储存样品，以沉淀蛋白质。</li>
	</ol></li>
	<li>蛋白质消化<ol>
<li>第二天，在10，000 x g 和4°C下，通过离心收集沉淀颗粒10分钟。 丢弃超纳坦剂，用 500μL 的 80% 丙酮清洗颗粒。重复共两次洗涤。洗涤后室温下空气干燥颗粒。</li>
		<li>在 8 M 尿素/40 mM HEPES 的 100 μL 中重新溶解蛋白颗粒，以确保在冰水浴中完全溶解、涡流或声波化 15 个周期的 30 s 开和 30 s 关闭。 注:尿素/HEPES 的体积调整取决于沉淀细胞颗粒的大小，如果发生改变，必须适当调整所有下游体积。</li>
		<li>根据制造商的说明，使用蛋白质检测（例如 BCA 蛋白质检测）量化蛋白质浓度，并通过 8 M 尿素/40 m M HEPES 的空白规范化调整背景测量。</li>
		<li>加入 300 μL 的 50 mM 碳酸氢铵，获得 2 M 尿素的最终浓度。 注:为下游测量实现蛋白质浓度正常化的机会，建议消化100微克蛋白质，并通过在液氮中闪光冻结来储存剩余未消化的样品，然后短期储存在-20°C或-80°C。</li>
		<li>在冰上加入2:50（v/w）的试金蛋白/Lys-C蛋白酶混合物的酶与蛋白质的比例，轻轻轻点管混合，在室温下孵育过夜。</li>
		<li>孵化后，通过在室温下加入1:10体积停止溶液（20%丙酮酸、6%三氟乙酸）和离心机样品，在10，000 x g 下停止消化5分钟。</li>
		<li>收集超纳坦（由消化的肽组成），并丢弃任何颗粒状碎片或沉淀物。</li>
	</ol></li>
	<li>肽脱盐<ol>
<li>通过在 1，000 x g 下添加 100 μL 的 100 μL 100% 丙酮和离心机，激活 C18 停止和去提取 （STAGE） 尖端（由 200 μL 移液器尖端中的 3 层 C18 树脂组成）。</li>
		<li>通过添加 50μL 的缓冲 B （80% （v/v） 丙酮、0.5% （v/v） 醋酸） 和离心机在 1，000 x g 2 分钟内，使 C18 STAGE 尖端保持平衡。</li>
		<li>通过添加 200 μL 的缓冲区 A （2% （v/v） 丙酮三酯、0.1% （v/v） 三氟乙酸、0.5% （v/v） 醋酸和离心机在 1，000 x g 3-5 分钟，使 C18 STAGE 尖端保持平衡。</li>
		<li>在 C18 STAGE 尖端和离心机中加入约 50μg 的消化样本，3-5 分钟，或直到样品通过自旋柱。 闪存将剩余的消化样本冻结在液氮中，并储存在 -20°C，直到需要为止。</li>
		<li>用 200μL 的缓冲区 A 和离心机在 1，000 x g 下清洗 C18 STAGE 尖端 3-5 分钟。</li>
		<li>在 C18 STAGE 尖端添加 50 μL 缓冲区 B，以 500 x g 的速度离心机 2 分钟。在 0.2 mL PCR 管中收集未清除的肽。</li>
		<li>在真空离心机中以最大速度干燥 30-40 分钟。完全干燥的样品可在室温下或 -20 °C 下储存，直至加工完毕。 注:干燥和脱盐肽是提交质谱处理设施的适当样品，可在环境温度下运输。</li>
	</ol></li>
</ol>6. 质谱
<ol><li>在 10 μL 缓冲区 A 中重组肽，并测量将 +1.5 至 3 μg 肽注入 MS 柱所需的浓度。样本量将取决于仪器仪表。</li>
	<li>使用预先确定的丙酮梯度（约 5-60%）在 0.5% 的醋酸在预期时间 （例如， 2 小时） 通过高性能液体色谱分离肽， 然后电喷电化到质谱仪。</li>
	<li>在数据依赖采集模式（m/z 300 至 1650）中使用高分辨率质谱仪获取 MS 扫描。 注意:梯度百分比和长度由实验和用户决定。精确的质谱仪设置取决于仪器仪表、实验和用户偏好。</li>
</ol>7. 数据分析
注:MS数据可以通过许多生物信息学管道进行处理。在此协议中，我们描述了使用公开的 MaxQuant 和 Perseus 平台的处理，但建议个人用户评估适合分析、偏好和使用的生物信息工具。
<ol><li>使用 MaxQuant 软件加载未处理的数据文件（直接来自 MS 仪器）。识别修改后的 MaxQuant 搜索参数下的蛋白质;使用目标诱饵方法识别蛋白质所需的至少两种独特的肽，假发现率为 1%，实现无标签量化与运行之间的匹配，将从 UniProt 数据库（即 新福尔曼斯 H99、 肌肉）获得的生物体 FASTA 文件合并，以识别和量化与仙女座搜索引擎的当前肽。咨询公共 MaxQuant 在线工具了解详细的教程（见 材料表）。</li>
	<li>将 MaxQuant 输出文件（"蛋白质组.txt"）上传到波斯。</li>
	<li>过滤包含潜在误报和污染物的行，以及仅通过站点肽与"基于分类列的过滤行"进行修改。</li>
	<li>在日志2 刻度上转换数据值。</li>
	<li>通过为行提供分类注释创建数据集组。</li>
	<li>按有效值筛选数据集，以定义蛋白质检测的截止点。 注意:对于严格而可靠的分析，建议提供 +50% 的识别率。例如，如果处理了四个副本，则将选择至少三个有效值。</li>
	<li>如果首选，则通过替换正常分布中的缺失值来将数据置换。 注:根据正常分布优化了被归责值，并提供了随机 LFQ 强度，以取代"NaN"占位符以模拟典型的丰度测量。此归责为需要可量化数据的下游统计分析提供了一个平台。</li>
	<li>在蛋白质行中添加注释（例如蛋白质名称、基因本体论术语）。 注:此 Perseus 工作流现已成为进一步生物信息处理、统计分析和数据可视化的强大框架，可咨询公共 Perseus 在线工具以获取详细的教程（见材料表）。</li>
</ol>

<ol>
	<li>Bongomin, F., Gago, S., Oladele, R., Denning, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Global+and+Multi-National+Prevalence+of+Fungal+Diseases-Estimate+Precision.">Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision.</a> Journal of Fungi. , (2017).</li><li>Tugume, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=HIV-Associated+cryptococcal+meningitis+occurring+at+relatively+higher+CD4+counts.">HIV-Associated cryptococcal meningitis occurring at relatively higher CD4 counts.</a> Journal of Infectious Diseases. 219 (6), 877-883 (2019).</li><li>Rajasingham, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Global+burden+of+disease+of+HIV-associated+cryptococcal+meningitis:+an+updated+analysis.">Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.</a> The Lancet Infectious Diseases. , (2017).</li><li>Perfect, J. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+antifungal+pipeline:+A+reality+check.">The antifungal pipeline: A reality check.</a> Nature Reviews Drug Discovery. , (2017).</li><li>Bermas, A., Geddes-McAlister, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Combatting+the+evolution+of+anti-fungal+resistance+in+Cryptococcus+neoformans.">Combatting the evolution of anti-fungal resistance in Cryptococcus neoformans.</a> Molecular Microbiology. , 1-14 (2020).</li><li>Geddes-McAlister, J., Shapiro, R. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=New+pathogens,+new+tricks:+Emerging,+drug-resistant+fungal+pathogens+and+future+prospects+for+antifungal+therapeutics.">New pathogens, new tricks: Emerging, drug-resistant fungal pathogens and future prospects for antifungal therapeutics.</a> Annals of the New York Academy of Sciences. , (2018).</li><li>Ball, B., Bermas, A., Carruthers-Lay, D., Geddes-McAlister, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mass+Spectrometry-Based+Proteomics+of+Fungal+Pathogenesis,+Host-Fungal+Interactions,+and+Antifungal+Development.">Mass Spectrometry-Based Proteomics of Fungal Pathogenesis, Host-Fungal Interactions, and Antifungal Development.</a> Journal of Fungi. , (2019).</li><li>Sukumaran, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Decoding+communication+patterns+of+the+innate+immune+system+by+quantitative+proteomics.">Decoding communication patterns of the innate immune system by quantitative proteomics.</a> J Leukocyte Biol. , (2019).</li><li>Salas, D., Stacey, R. G., Akinlaja, M., Foster, L. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Next-generation+interactomics:+Considerations+for+the+use+of+co-elution+to+measure+protein+interaction+networks.">Next-generation interactomics: Considerations for the use of co-elution to measure protein interaction networks.</a> Molecular and Cellular Proteomics. , (2020).</li><li>Aebersold, R., Mann, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mass-spectrometric+exploration+of+proteome+structure+and+function.">Mass-spectrometric exploration of proteome structure and function.</a> Nature. 537 (7620), 347-355 (2016).</li><li>Mann, M., Kulak, N. A., Nagaraj, N., Cox, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Coming+Age+of+Complete,+Accurate,+and+Ubiquitous+Proteomes.">The Coming Age of Complete, Accurate, and Ubiquitous Proteomes.</a> Molecular Cell. 49 (4), 583-590 (2013).</li><li>Cox, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Accurate+Proteome-wide+Label-free+Quantification+by+Delayed+Normalization+and+Maximal+Peptide+Ratio+Extraction,+Termed+MaxLFQ.">Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ.</a> Molecular &amp; Cellular Proteomics. 13 (9), 2513-2526 (2014).</li><li>Ankney, J. A., Muneer, A., Chen, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Relative+and+Absolute+Quantitation+in+Mass+Spectrometry-Based+Proteomics.">Relative and Absolute Quantitation in Mass Spectrometry-Based Proteomics.</a> Annual Review of Analytical Chemistry. , (2018).</li><li>Cox, J., Mann, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=MaxQuant+enables+high+peptide+identification+rates,+individualized+p.p.b.-range+mass+accuracies+and+proteome-wide+protein+quantification.">MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.</a> Nature Biotechnology. 26 (12), 1367-1372 (2008).</li><li>Tyanova, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Perseus+computational+platform+for+comprehensive+analysis+of+(prote)omics+data.">The Perseus computational platform for comprehensive analysis of (prote)omics data.</a> Nature Methods. 13 (9), 731-740 (2016).</li><li>Cox, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Andromeda:+A+peptide+search+engine+integrated+into+the+MaxQuant+environment.">Andromeda: A peptide search engine integrated into the MaxQuant environment.</a> Journal of Proteome Research. , (2011).</li><li>Zhong, Z., Pirofski, L. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Opsonization+of+Cryptococcus+neoformans+by+human+anticryptococcal+glucuronoxylomannan+antibodies.">Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies.</a> Infection and Immunity. , (1996).</li><li>Nicola, A. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Macrophage+autophagy+in+immunity+to+Cryptococcus+neoformans+and+Candida+albicans.">Macrophage autophagy in immunity to Cryptococcus neoformans and Candida albicans.</a> Infection and Immunity. , (2012).</li><li>Ball, B., Geddes-McAlister, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Quantitative+Proteomic+Profiling+of+Cryptococcus+neoformans.">Quantitative Proteomic Profiling of Cryptococcus neoformans.</a> Current Protocols in Microbiology. , (2019).</li><li>Geddes-McAlister, J., Gadjeva, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mass+spectromerty-based+quantitative+proteomics+of+murine-derived+polymorphonuclear+neutrophils.">Mass spectromerty-based quantitative proteomics of murine-derived polymorphonuclear neutrophils.</a> Current Protocols in Immunology. , (2019).</li><li>Geddes, J. M. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Secretome+profiling+of+Cryptococcus+neoformans+reveals+regulation+of+a+subset+of+virulence-associated+proteins+and+potential+biomarkers+by+protein+kinase+A.">Secretome profiling of Cryptococcus neoformans reveals regulation of a subset of virulence-associated proteins and potential biomarkers by protein kinase A.</a> BMC Microbiology. , (2015).</li><li>Geddes, J. M. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Analysis+of+the+protein+kinase+a-regulated+proteome+of+Cryptococcus+neoformans+identifies+a+role+for+the+ubiquitin-proteasome+pathway+in+capsule+formation.">Analysis of the protein kinase a-regulated proteome of Cryptococcus neoformans identifies a role for the ubiquitin-proteasome pathway in capsule formation.</a> mBio. 7 (1), 1-15 (2016).</li><li>Al Shweiki, M. H. D. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Assessment+of+Label-Free+Quantification+in+Discovery+Proteomics+and+Impact+of+Technological+Factors+and+Natural+Variability+of+Protein+Abundance.">Assessment of Label-Free Quantification in Discovery Proteomics and Impact of Technological Factors and Natural Variability of Protein Abundance.</a> Journal of Proteome Research. , (2017).</li><li>Ong, S. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Stable+Isotope+Labeling+by+Amino+Acids+in+Cell+Culture,+SILAC,+as+a+Simple+and+Accurate+Approach+to+Expression+Proteomics.">Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics.</a> Molecular &amp; Cellular Proteomics. 1 (5), 376-386 (2002).</li><li>Thompson, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tandem+mass+tags:+A+novel+quantification+strategy+for+comparative+analysis+of+complex+protein+mixtures+by+MS/MS.">Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS.</a> Analytical Chemistry. 75 (8), 1895-1904 (2003).</li><li>Borner, G. H. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Organellar+Maps+Through+Proteomic+Profiling+-+A+Conceptual+Guide.">Organellar Maps Through Proteomic Profiling - A Conceptual Guide.</a> Molecular &amp; Cellular Proteomics. , (2020).</li><li>Gingras, A. C., Abe, K. T., Raught, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Getting+to+know+the+neighborhood:+using+proximity-dependent+biotinylation+to+characterize+protein+complexes+and+map+organelles.">Getting to know the neighborhood: using proximity-dependent biotinylation to characterize protein complexes and map organelles.</a> Current Opinion in Chemical Biology. , (2019).</li><li>Kugadas, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Frontline+Science:+Employing+enzymatic+treatment+options+for+management+of+ocular+biofilm-based+infections.">Frontline Science: Employing enzymatic treatment options for management of ocular biofilm-based infections.</a> Journal of Leukocyte Biology. , (2019).</li><li>Yeung, J., Gadjeva, M., Geddes-McAlister, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Label-Free+Quantitative+Proteomics+Distinguishes+General+and+Site-Specific+Host+Responses+to+Pseudomonas+aeruginosa+Infection+at+the+Ocular+Surface.">Label-Free Quantitative Proteomics Distinguishes General and Site-Specific Host Responses to Pseudomonas aeruginosa Infection at the Ocular Surface.</a> Proteomics. , (2020).</li><li>Yeung, J., Lamb, J., Krieger, J. R., Gadjeva, M., Geddes-McAlister, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Quantitative+Proteomic+Profiling+ofMurine+Ocular+Tissue+and+theExtracellular+Environment.">Quantitative Proteomic Profiling ofMurine Ocular Tissue and theExtracellular Environment.</a> Current Protocols in Mouse Biology. 10 (83), (2020).</li></ol>

作者声明没有利益冲突。

协议中的关键步骤包括制备巨噬细胞和收集用于蛋白质加工的共同培养样本，尽量减少对细胞的干扰。重要的是要执行步骤，清洗，接种，并删除粘附的巨噬细胞轻轻地和仔细，以防止不必要的裂解细胞之前收集。建立正确的实验MOI也至关重要，因为接种过高的MOI会导致快速的巨噬细胞死亡和MS的收集和处理样本的困难。 相反，低MOI数量将导致噬菌体真菌细胞减少，生物系统中真菌蛋白的检测有?...

侵入性真菌感染的流行率正在大大增加，与不可接受的高死亡率有关，最常见的报告在有免疫缺陷倾向1的个人。隐球菌是一种臭名昭著的机会性真菌病原体，能够在宿主巨噬细胞内细胞内细胞内存活。抗真菌干预不足导致真菌传播和危及生命的隐球菌脑膜炎和脑膜炎2，3。全球免疫功能化地位的提高要求同时增加抗真菌剂的使用，其中许多真菌物种，包括C.新福曼，已经逐渐进化到4，5，6的抗药性。因此，必须实施有力和有效的技术，以回答有关宿主防御反应和微生物发病机制的重要生物问题。
质谱学技术进步的新时代，包括强大的计算和生物信息管道的产生，为大规模分析宿主病原体研究提供了基础。传统的发病机制驱动的蛋白质组分析通常从宿主或病原体的角度描述感染的观点，包括综合方法，如蛋白质相关性分析，亲和色谱结合蛋白质组学，和相互作用经济学9。对宿主系统中危险病原体毒性的调查具有巨大的临床意义:然而，在单个实验中应用双重透视分析以前被认为是无法实现的。例如，病原体对感染的看法往往被高度丰富的宿主蛋白所淹没，导致检测低富真菌蛋白7的敏感性降低。此外，高样本复杂性邀请许多目标在单个实验系统中进行调查，并证明很难阐明特定病原体蛋白的行动机制。
自下而上的蛋白组学是一种流行的MS技术，它使可管理的样品制备，其中肽产生序列特异性酶消化，然后液体色谱分离，识别和量化MS10，11。在这里，我们演示了一种基于数据的获取策略的方法，旨在实现基于感染的蛋白质组或"感染体"的公正覆盖。具体来说，无标签量化（LFQ）可以摆脱对化学或代谢标签的依赖，从而对多个蛋白质组的蛋白质水平变化进行可靠和准确的识别，从而减少样品处理和处理步骤12、13。这种普遍应用在细胞内的某一时刻询问产生的蛋白质，而该细胞独立于任何预期的蛋白质生产:因此，可能会发现对感染至关重要的新见解。
此处描述的工作流程进行了优化，以探索 C.新福尔曼在与 宿主免疫细胞的感染模仿条件下的蛋白质水平变化（图1）。这种方法不是依靠细胞类型的分离和分离，而是将宿主和病原体蛋白质组分离在一起，并利用生物信息分离利用两个生物特定的数据库来区分特定物种的蛋白质生产。这种方法为无限数量的样品处理提供了优势，无需同位素标签研究或分数所需的额外成本高昂的制备步骤。此外，此工作流程支持可转移到各种真菌和细菌病原体的优化蛋白质提取方案，这些病原体能够瞄准和感染宿主免疫细胞。总体而言，该协议概述了完成高分辨率MS的公正蛋白质提取和样品处理的步骤，然后是数据和统计分析，能够提供大量对感染具有重要意义的真菌蛋白知识，并结合对宿主防御反应的全面分析。

<table>
	<tbody>
		<tr>
			<td>100 mM Tris-HCl, pH 8.5</td>
			<td>Fisher Scientific</td>
			<td>BP152-1</td>
			<td>Maintain at 4&#176;C</td>
		</tr>
		<tr>
			<td>60 x 15 mm Dish, Nunclon Delta</td>
			<td>ThermoFisher Scientific</td>
			<td>174888</td>
			<td></td>
		</tr>
		<tr>
			<td>6-well cell culture plate</td>
			<td>ThermoFisher Scientific</td>
			<td>140675</td>
			<td></td>
		</tr>
		<tr>
			<td>Acetonitrile, MS grade</td>
			<td>Pierce</td>
			<td>TS-51101</td>
			<td></td>
		</tr>
		<tr>
			<td>Acetic Acid</td>
			<td>Sigma Aldrich</td>
			<td>1099510001</td>
			<td></td>
		</tr>
		<tr>
			<td>Acetone</td>
			<td>Sigma Aldrich</td>
			<td>34850-1L</td>
			<td></td>
		</tr>
		<tr>
			<td>Ammonium bicarbonate (ABC)</td>
			<td>ThermoFisher Scientific</td>
			<td>A643-500</td>
			<td>Prepare a stock 50 mM ABC solution, stable at room temperature for up to one month.</td>
		</tr>
		<tr>
			<td>Bel-Art&#8482; HiFlow Vacuum Aspirator Collection System</td>
			<td>Fisher Scientific</td>
			<td>13-717-300</td>
			<td>Not essential, serological pipettes can be used to remove media.</td>
		</tr>
		<tr>
			<td>C18 resin</td>
			<td>3M Empore</td>
			<td>3M2215</td>
			<td></td>
		</tr>
		<tr>
			<td>Cell Scrapers</td>
			<td>VWR</td>
			<td>10062-906</td>
			<td>Not essential, other methods to release macrophage cells can be used.</td>
		</tr>
		<tr>
			<td>Centrifugal vaccuum concentrator</td>
			<td>Eppendorf</td>
			<td>07-748-15</td>
			<td></td>
		</tr>
		<tr>
			<td>Complete Filtration Unit</td>
			<td>VWR</td>
			<td>10040-436</td>
			<td></td>
		</tr>
		<tr>
			<td>Conical falcon tubes (15 mL)</td>
			<td>Fisher Scientific</td>
			<td>05-539-12</td>
			<td></td>
		</tr>
		<tr>
			<td>Countess II Automated Cell Counter</td>
			<td>ThermoFisher Scientific</td>
			<td>AMQAX1000</td>
			<td>Not essential, haemocytometer can be used as an alternative.</td>
		</tr>
		<tr>
			<td>CytoTox 96 Non-Radioactive Cytotoxicity Assay</td>
			<td>Promega</td>
			<td>G1780</td>
			<td></td>
		</tr>
		<tr>
			<td>Dithiothreitol (DTT)</td>
			<td>ThermoFisher Scientific</td>
			<td>R0861</td>
			<td>Prepare bulk stock solution of 1 M DTT, flash frozen and stored at -20 &#176;C until use. Discard after each use (do not freeze-thaw repeatedly).</td>
		</tr>
		<tr>
			<td>DMEM, high glucose, GlutaMAX Supplement</td>
			<td>ThermoFisher Scientific</td>
			<td>10566016</td>
			<td></td>
		</tr>
		<tr>
			<td>Fetal Bovine Serum (FBS)</td>
			<td>ThermoFisher Scientific</td>
			<td>12483020</td>
			<td>Heat inactivate by incubating at 60&#176;C for 30 minutes. Prepare 50 ml aliquots and flash freeze. Thaw prior to media preparation</td>
		</tr>
		<tr>
			<td>Haemocytometer</td>
			<td>VWR</td>
			<td>15170-208</td>
			<td></td>
		</tr>
		<tr>
			<td>HEPES</td>
			<td>Sigma Aldrich</td>
			<td>H3375</td>
			<td>Prepare 40 mM HEPES/8 M Urea in bulk stock solution, flash frozen, store at -20&#176;C until use. Discard after each use (do not freeze-thaw repeatedly).</td>
		</tr>
		<tr>
			<td>High-performance liquid chromatography system</td>
			<td>ThermoFisher Scientific</td>
			<td>LC140</td>
			<td>Gradient length is based on sample complexity, recommended 120 min gradient for infectome samples.</td>
		</tr>
		<tr>
			<td>High-resolution mass spectrometer</td>
			<td>ThermoFisher Scientific</td>
			<td>726042</td>
			<td></td>
		</tr>
		<tr>
			<td>Iodoacetamide (IAA)</td>
			<td>Sigma Aldrich</td>
			<td>I6125</td>
			<td>Prepare 0.55 M bulk stock solution, flash frozen, store at -20&#176;C until use. Discard after each use (do not freeze-thaw repeatedly).</td>
		</tr>
		<tr>
			<td>L-glutamine</td>
			<td>ThermoFisher Scientific</td>
			<td>25030081</td>
			<td>Can be aliquot and frozen for storage. Thaw prior to media preparation.</td>
		</tr>
		<tr>
			<td>LoBind Microcentrifuge tubes</td>
			<td>Eppendorf</td>
			<td>13-698-794</td>
			<td></td>
		</tr>
		<tr>
			<td>MaxQuant</td>
			<td>https://maxquant.org/</td>
			<td></td>
			<td>MaxQuant is a public platform that offers tutorials, such as the MaxQuant Summer School, outlining the computational analysis steps of large MS data sets</td>
		</tr>
		<tr>
			<td>Microcentrifuge</td>
			<td>Eppendorf</td>
			<td>13864457</td>
			<td></td>
		</tr>
		<tr>
			<td>Penicillin : Streptomycin 10k/10k</td>
			<td>VWR</td>
			<td>CA12001-692</td>
			<td>Can be aliquot and frozen for storage. Thaw prior to media preparation.</td>
		</tr>
		<tr>
			<td>Peptide separation columns</td>
			<td>ThermoFisher Scientific</td>
			<td>ES803</td>
			<td></td>
		</tr>
		<tr>
			<td>Perseus Software</td>
			<td>http://maxquant.net/perseus/</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Phosphate Buffered Saline</td>
			<td>VWR</td>
			<td>CA12001-676</td>
			<td>Puchase not required. PBS can also be prepared but sterile filteration must be performed before use.</td>
		</tr>
		<tr>
			<td>Pierce BCA Protein Assay</td>
			<td>ThermoFisher Scientific</td>
			<td>&#160;23225</td>
			<td></td>
		</tr>
		<tr>
			<td>Pipette, Disposable Serological (10 mL)</td>
			<td>Fisher Scientific</td>
			<td>13-678-11E</td>
			<td></td>
		</tr>
		<tr>
			<td>Pipette, Disposable Serological (25 mL) Basix</td>
			<td>Fisher Scientific</td>
			<td>14955235</td>
			<td></td>
		</tr>
		<tr>
			<td>Probe sonciator</td>
			<td>ThermoFisher Scientific</td>
			<td>100-132-894</td>
			<td></td>
		</tr>
		<tr>
			<td>Protease inhibitor cocktail tablet</td>
			<td>Roche</td>
			<td>4693159001</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium dodecyl sulfate</td>
			<td>ThermoFisher Scientific</td>
			<td>28364</td>
			<td>20% (w/v)</td>
		</tr>
		<tr>
			<td>Spectrophotometer (Nanodrop)</td>
			<td>ThermoFisher Scientific</td>
			<td>ND-2000</td>
			<td></td>
		</tr>
		<tr>
			<td>STAGE tipping centrifuge</td>
			<td>Sonation</td>
			<td>STC-V2</td>
			<td></td>
		</tr>
		<tr>
			<td>Thermal Shaker</td>
			<td>VWR</td>
			<td>NO89232-908</td>
			<td></td>
		</tr>
		<tr>
			<td>Trifluoroacetic acid</td>
			<td>ThermoFisher Scientific</td>
			<td>85183</td>
			<td></td>
		</tr>
		<tr>
			<td>Trypsin/Lys-C protease mix, MS grade</td>
			<td>Pierce</td>
			<td>A40007</td>
			<td>Maintain at -20 &#176;C.</td>
		</tr>
		<tr>
			<td>Ultrasonic bath</td>
			<td>Bransonic</td>
			<td>A89375-450</td>
			<td>Stored in cold room (4C)</td>
		</tr>
		<tr>
			<td>Urea</td>
			<td>Sigma Aldrich</td>
			<td>U1250-1KG</td>
			<td>Prepare 40 mM HEPES/8 M Urea in bulk stock solution, flash frozen, store at -20 &#176;C until use. Discard after each use (do not freeze-thaw repeatedly).</td>
		</tr>
		<tr>
			<td>Yeast-extract peptone dextrose broth</td>
			<td>BD Difco</td>
			<td>BM20</td>
			<td></td>
		</tr>
	</tbody>
</table>

label-free quantitative proteomics workflow for discovery-driven host-pathogen interactions

基于质谱学（MS）的定量蛋白质组学的技术成就为分析生物体在不同条件下的全球蛋白质组开辟了许多未被发现的途径。这种强大的策略应用于微生物病原体与所需宿主的相互作用，全面地描绘了两种感染视角。在此，工作流描述了 密码球菌新福尔曼的 感染物的无标签量化（LFQ），这是一种真菌诱发性细胞内病原体，是致命疾病隐科病的致病剂，存在不朽的巨噬细胞。该协议在单个实验中详细说明了病原体和哺乳动物细胞的适当蛋白质制备技术，从而为液相色谱 （LC） -MS/MS 分析提交了适当的肽。LFQ 的高通量通用性允许广泛的蛋白质识别和量化动态范围，以及可转移到任何宿主病原体感染设置，保持极端敏感性。该方法进行了优化，以编目感染模仿条件下病原体的广泛、公正的蛋白质丰度配置文件。具体来说，这里演示的方法提供了关于 C.新福尔曼病 原体的基本信息，例如毒性所需的蛋白质生产，并识别出对微生物入侵作出反应的关键宿主蛋白。

上述协议允许在单个实验中识别和量化来自真菌病原体C.新福尔曼和宿主巨噬细胞的蛋白质。在共同培养之后，细胞被收集和处理在一起，并根据每个物种特有的肽谱进行生物信息分离。这是定义感染期间宿主-病原体关系相互作用的有力方法。从实验中识别出的蛋白质数量取决于启动材料、样品准备、梯度长度、MS 仪器和生物信息工作流程。使用此处描述的协议，我们通常从实验中识别出?...

Watch this Scientific Journal Video about Label-Free Quantitative Proteomics Workflow for Discovery-Driven Host-Pathogen Interactions at JoVE.com

Label-Free Quantitative Proteomics Workflow for Discovery-Driven Host-Pathogen Interactions

在这里，我们提出了一个协议，以分析宿主和病原体之间的相互作用，在感染基于质谱学的蛋白组学。此协议使用无标签量化来测量宿主（例如巨噬细胞）和病原体（例如 新福尔曼隐球菌）的蛋白质丰度变化。

无标签定量蛋白经济学工作流程，用于发现驱动的宿主-病原体交互

The technological achievements of mass spectrometry (MS)-based quantitative proteomics opens many undiscovered avenues for analyzing an organism&#8217;s ...

label-free-quantitative-proteomics-workflow-for-discovery-driven-host

Research

JoVE Journal

Immunology and Infection

6.5K 次观看.  University of Guelph. 在这里，我们提出了一个协议，以分析宿主和病原体之间的相互作用，在感染基于质谱学的蛋白组学。此协议使用无标签量化来测量宿主（例如巨噬细胞）和病原体（例如 新福尔曼隐球菌）的蛋白质丰度变化。

视频: Label-Free Quantitative Proteomics Workflow for Discovery-Driven Host-Pathogen Interactions

Use of an Optical Trap for Study of Host-Pathogen Interactions for Dynamic Live Cell Imaging

Dynamic live cell imaging allows direct visualization of real-time interactions between cells of the immune system1, 2; however, the lack of spatial and temporal control between the phagocytic cell and microbe has rendered focused observations into the initial interactions of host response to pathogens difficult. Historically, intercellular contact events such as phagocytosis3 have been imaged by mixing two cell types, and then continuously scanning the field-of-view to find serendipitous intercellular contacts at the appropriate stage of interaction. The stochastic nature of these events renders this process tedious, and it is difficult to observe early or fleeting events in cell-cell contact by this approach. This method requires finding cell pairs that are on the verge of contact, and observing them until they consummate their contact, or do not. To address these limitations, we use optical trapping as a non-invasive, non-destructive, but fast and effective method to position cells in culture.
Optical traps, or optical tweezers, are increasingly utilized in biological research to capture and physically manipulate cells and other micron-sized particles in three dimensions4. Radiation pressure was first observed and applied to optical tweezer systems in 19705, 6, and was first used to control biological specimens in 19877. Since then, optical tweezers have matured into a technology to probe a variety of biological phenomena8-13.
We describe a method14 that advances live cell imaging by integrating an optical trap with spinning disk confocal microscopy with temperature and humidity control to provide exquisite spatial and temporal control of pathogenic organisms in a physiological environment to facilitate interactions with host cells, as determined by the operator. Live, pathogenic organisms like Candida albicans and Aspergillus fumigatus, which can cause potentially lethal, invasive infections in immunocompromised individuals15, 16 (e.g. AIDS, chemotherapy, and organ transplantation patients), were optically trapped using non-destructive laser intensities and moved adjacent to macrophages, which can phagocytose the pathogen. High resolution, transmitted light and fluorescence-based movies established the ability to observe early events of phagocytosis in living cells. To demonstrate the broad applicability in immunology, primary T-cells were also trapped and manipulated to form synapses with anti-CD3 coated microspheres in vivo, and time-lapse imaging of synapse formation was also obtained. By providing a method to exert fine spatial control of live pathogens with respect to immune cells, cellular interactions can be captured by fluorescence microscopy with minimal perturbation to cells and can yield powerful insight into early responses of innate and adaptive immunity.

A method is described to individually select, manipulate, and image live pathogens using an optical trap coupled to a spinning disk microscope. The optical trap provides spatial and temporal control of organisms and places them adjacent to host cells. Fluorescence microscopy captures dynamic intercellular interactions with minimal perturbation to cells.

动态活细胞成像的宿主 - 病原体相互作用的研究使用的光学陷阱

Dynamic live cell imaging allows direct visualization of real-time interactions between cells of the immune system1, 2; however, the lack of spatial and ...

科研

免疫与感染

Use of the EpiAirway Model for Characterizing Long-term Host-pathogen Interactions

Nontypeable Haemophilus influenzae (NTHi) are human-adapted Gram-negative bacteria that can cause recurrent and chronic infections of the respiratory mucosa 1; 2. To study the mechanisms by which these organisms survive on and inside respiratory tissues, a model in which successful long-term co-culture of bacteria and human cells can be performed is required. We use primary human respiratory epithelial tissues raised to the air-liquid interface, the EpiAirway model (MatTek, Ashland, MA). These are non-immortalized, well-differentiated, 3-dimensional tissues that contain tight junctions, ciliated and nonciliated cells, goblet cells that produce mucin, and retain the ability to produce cytokines in response to infection. 
This biologically relevant in vitro model of the human upper airway can be used in a number of ways; the overall goal of this method is to perform long-term co-culture of EpiAirway tissues with NTHi and quantitate cell-associated and internalized bacteria over time. As well, mucin production and the cytokine profile of the infected co-cultures can be determined. This approach improves upon existing methods in that many current protocols use submerged monolayer or Transwell cultures of human cells, which are not capable of supporting bacterial infections over extended periods3. For example, if an organism can replicate in the overlying media, this can result in unacceptable levels of cytotoxicity and loss of host cells, arresting the experiment. The EpiAirway model allows characterization of long-term host-pathogen interactions. Further, since the source for the EpiAirway is normal human tracheo-bronchial cells rather than an immortalized line, each is an excellent representation of actual human upper respiratory tract tissue, both in structure and in function4.
For this method, the EpiAirway tissues are weaned off of anti-microbial and anti-fungal compounds for 2 days prior to delivery, and all procedures are performed under antibiotic-free conditions. This necessitates special considerations, since both bacteria and primary human tissues are used in the same biosafety cabinet, and are co-cultured for extended periods.

This method allows characterization of extended bacterial co-culture with EpiAirways, primary human respiratory epithelial tissue grown at the air-liquid interface, a biologically relevant in vitro model. The approach can be used with any microbe that is amenable to long-term co-culture.

使用的EpiAirway模型，用于描述长期宿主 - 病原体相互作用

Nontypeable Haemophilus influenzae  (NTHi) are human-adapted Gram-negative bacteria that can cause recurrent and chronic infections of the respiratory ...

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Significant efforts were gathered to generate large-scale comprehensive protein-protein interaction network maps. This is instrumental to understand the pathogen-host relationships and was essentially performed by genetic screenings in yeast two-hybrid systems. The recent improvement of protein-protein interaction detection by a Gaussia luciferase-based fragment complementation assay now offers the opportunity to develop integrative comparative interactomic approaches necessary to rigorously compare interaction profiles of proteins from different pathogen strain variants against a common set of cellular factors.
This paper specifically focuses on the utility of combining two orthogonal methods to generate protein-protein interaction datasets: yeast two-hybrid (Y2H) and a new assay, high-throughput Gaussia princeps protein complementation assay (HT-GPCA) performed in mammalian cells.
A large-scale identification of cellular partners of a pathogen protein is performed by mating-based yeast two-hybrid screenings of cDNA libraries using multiple pathogen strain variants. A subset of interacting partners selected on a high-confidence statistical scoring is further validated in mammalian cells for pair-wise interactions with the whole set of pathogen variants proteins using HT-GPCA. This combination of two complementary methods improves the robustness of the interaction dataset, and allows the performance of a stringent comparative interaction analysis. Such comparative interactomics constitute a reliable and powerful strategy to decipher any pathogen-host interplays.

This article focuses on the identification of high-confident interaction datasets between host and pathogen proteins using a combination of two orthogonal methods: yeast two-hybrid followed by a high-throughput interaction assay in mammalian cells called HT-GPCA.

比较方法来表征景观的宿主 - 病原体蛋白 - 蛋白相互作用

Significant efforts were gathered to generate  large-scale comprehensive protein-protein interaction network maps. This is  instrumental to understand the ...

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

According to the American Cancer Society, more than 200,000 women will be diagnosed with invasive breast cancer each year and approximately 40,000 will die from the disease. The human leukocyte antigen (HLA) class I samples peptides derived from proteasomal degradation of cellular proteins and presents these fragments on the cell surface for interrogation by circulating cytotoxic T lymphocytes (CTL). Generation of T-cell receptor mimic (TCRm) monoclonal antibodies (mAbs) which recognize breast cancer specific peptide/HLA-A*02:01 complexes such as those derived from macrophage migration inhibitory factor (MIF19-27) and NY-ESO-1157-165 enable detection and destruction of breast cancer cells in the absence of an effective anti-tumor CTL response. Intact class I HLA/peptide complexes are shed by breast cancer cells and represent potentially relevant cancer biomarkers. In this work, a breakthrough biomarker screening system for cancer diagnostics incorporating T-cell receptor mimic monoclonal antibodies combined with a novel, label-free biosensor utilizing guided-mode resonance (GMR) sensor technology is presented. Detection of shed MIF/HLA-A*02:01 complexes in MDA-MB-231 cell supernatants, spiked human serum, and patient plasma is demonstrated. The impact of this work could revolutionize personalized medicine through development of companion disease diagnostics for targeted immunotherapies.

Intact class I HLA/peptide complexes are shed by cancer cells, representing a potential relevant cancer biomarker. Utilizing label-free sensor technology and T-cell receptor mimicking monoclonal antibodies, detection of shed MIF/HLA-A*02:01 complexes in MDA-MB-231 cell supernatants, spiked human serum, and patient plasma is demonstrated, enabling development of a novel cancer diagnostic platform.

在乳腺癌检测人类白细胞抗原生物标志物的利用无标记生物传感技术

According to the American Cancer Society, more than 200,000 women will be diagnosed with invasive breast cancer each year and approximately 40,000 will ...

Electroporation of Functional Bacterial Effectors into Mammalian Cells

The study of protein interactions in the context of living cells can generate critical information about localization, dynamics, and interacting partners. This information is particularly valuable in the context of host-pathogen interactions. Many pathogen proteins function within host cells in a variety of way such as, enabling evasion of the host immune system and survival within the intracellular environment. To study these pathogen-protein host-cell interactions, several approaches are commonly used, including: in vivo infection with a strain expressing a tagged or mutant protein, or introduction of pathogen genes via transfection or transduction. Each of these approaches has advantages and disadvantages. We sought a means to directly introduce exogenous proteins into cells. Electroporation is commonly used to introduce nucleic acids into cells, but has been more rarely applied to proteins although the biophysical basis is exactly the same. A standard electroporator was used to introduce affinity-tagged bacterial effectors into mammalian cells. Human epithelial and mouse macrophage cells were cultured by traditional methods, detached, and placed in 0.4 cm gap electroporation cuvettes with an exogenous bacterial pathogen protein of interest (e.g. Salmonella Typhimurium GtgE). After electroporation (0.3 kV) and a short (4 hr) recovery period, intracellular protein was verified by fluorescently labeling the protein via its affinity tag and examining spatial and temporal distribution by confocal microscopy. The electroporated protein was also shown to be functional inside the cell and capable of correct subcellular trafficking and protein-protein interaction. While the exogenous proteins tended to accumulate on the surface of the cells, the electroporated samples had large increases in intracellular effector concentration relative to incubation alone. The protocol is simple and fast enough to be done in a parallel fashion, allowing for high-throughput characterization of pathogen proteins in host cells including subcellular targeting and function of virulence proteins.

Electroporation was used to insert purified bacterial virulence effector proteins directly into living eukaryotic cells. Protein localization was monitored by confocal immunofluorescence microscopy. This method allows for studies on trafficking, function, and protein-protein interactions using active exogenous proteins, avoiding the need for heterologous expression in eukaryotic cells.

电功能性细菌效应器到哺乳动物细胞

The study of protein interactions in the context of living cells can generate critical information about localization, dynamics, and interacting partners. ...

Label-free Neutrophil Enrichment from Patient-derived Airway Secretion Using Closed-loop Inertial Microfluidics

Airway secretions contain a large number of immune-related cells, e.g., neutrophils, macrophages, and lymphocytes, which can be used as a major resource to evaluate a variety of pulmonary diseases, both for research and clinical purposes. However, due to the heterogeneous and viscous nature of patient mucus, there is currently no reliable dissociation method that does not damage the host immune cells in the patient airway secretion. In this research, we introduce a sample preparation method that uses inertial microfluidics for the patient&#39;s immune assessment. Regardless of the heterogeneous fluidic properties of the clinical samples, the proposed method recovers more than 95% of neutrophils from airway secretion samples that are diluted 1,000-fold with milliliters of clean saline. By recirculating the concentrated output stream to the initial sample reservoir, a high concentration, recovery, and purity of the immune cells are provided; recirculation is considered a trade-off to the single-run syringe-based operation of inertial microfluidics. The closed-loop operation of spiral microfluidics provides leukocytes without physical or chemical disturbance, as demonstrated by the phorbol 12-myristate 13-acetate (PMA)-induced elastase release of sorted neutrophils.

In this research, we demonstrate a label-free neutrophil separation method from clinical airway secretions using closed-loop operation of spiral inertial microfluidics. The proposed method would expand the clinical in vitro assays for various respiratory diseases.

闭环惯性微流体在患者源气道分泌物中无标签中性粒细胞富集的应用

Airway secretions contain a large number of immune-related cells, e.g., neutrophils, macrophages, and lymphocytes, which can be used as a major resource ...

Label-Free Identification of Lymphocyte Subtypes Using Three-Dimensional Quantitative Phase Imaging and Machine Learning

We describe here a protocol for the label-free identification of lymphocyte subtypes using quantitative phase imaging and machine learning. Identification of lymphocyte subtypes is important for the study of immunology as well as diagnosis and treatment of various diseases. Currently, standard methods for classifying lymphocyte types rely on labeling specific membrane proteins via antigen-antibody reactions. However, these labeling techniques carry the potential risks of altering cellular functions. The protocol described here overcomes these challenges by exploiting intrinsic optical contrasts measured by 3D quantitative phase imaging and a machine learning algorithm. Measurement of 3D refractive index (RI) tomograms of lymphocytes provides quantitative information about 3D morphology and phenotypes of individual cells. The biophysical parameters extracted from the measured 3D RI tomograms are then quantitatively analyzed with a machine learning algorithm, enabling label-free identification of lymphocyte types at a single-cell level. We measure the 3D RI tomograms of B, CD4+ T, and CD8+ T lymphocytes and identified their cell types with over 80% accuracy. In this protocol, we describe the detailed steps for lymphocyte isolation, 3D quantitative phase imaging, and machine learning for identifying lymphocyte types.

We describe a protocol for the label-free identification of lymphocyte subtypes using quantitative phase imaging and a machine learning algorithm. Measurements of 3D refractive index tomograms of lymphocytes present 3D morphological and biochemical information for individual cells, which is then analyzed with a machine-learning algorithm for identification of cell types.

用三维定量相位成像和机器学习技术对淋巴细胞亚型进行无标签鉴定

We describe here a protocol for the label-free identification of lymphocyte subtypes using quantitative phase imaging and machine learning. Identification ...

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Vaccines are a 20th century medical marvel. They have dramatically reduced the morbidity and mortality caused by infectious diseases and contributed to a striking increase in life expectancy around the globe. Nonetheless, determining vaccine efficacy remains a challenge. Emerging evidence suggests that the current acellular vaccine (aPV) for Bordetella pertussis (B. pertussis) induces suboptimal immunity. Therefore, a major challenge is designing a next-generation vaccine that induces protective immunity without the adverse side effects of a whole-cell vaccine (wPV). Here we describe a protocol that we used to test the efficacy of a promising, novel adjuvant that skews immune responses to a protective Th1/Th17 phenotype and promotes a better clearance of a B. pertussis challenge from the murine respiratory tract. This article describes the protocol for mouse immunization, bacterial inoculation, tissue harvesting, and analysis of immune responses. Using this method, within our model, we have successfully elucidated crucial mechanisms elicited by a promising, next-generation acellular pertussis vaccine. This method can be applied to any infectious disease model in order to determine vaccine efficacy.

Here we present an elegant protocol for in vivo evaluation of vaccine effectiveness and host immune responses. This protocol can be adapted for vaccine models that study viral, bacterial, or parasitic pathogens.

宿主病原学反应及疫苗效果评价

Vaccines are a 20th century medical marvel. They have dramatically reduced the morbidity and mortality caused by infectious diseases and contributed to a ...

Infection of Zebrafish Larvae with Aspergillus Spores for Analysis of Host-Pathogen Interactions

Invasive aspergillosis (IA) is one of&#160;the most common fungal infections among immunocompromised individuals. Despite the availability of antifungal drugs, IA can cause &#62;50% mortality in infected immunocompromised patients. It is crucial to determine both host and pathogen factors that contribute to infection susceptibility and low survival rates in infected patients in order to develop novel therapeutics. Innate immune responses play a pivotal role in recognition and clearance of Aspergillus spores, though little is known about the exact cellular and molecular mechanisms. Reliable models are required to investigate detailed mechanistic interactions between the host and pathogen. The optical clarity and genetic tractability of zebrafish larvae make them an intriguing model&#160;to study host-pathogen interactions of multiple human bacterial and fungal infections in a live and intact host. This protocol describes a larval zebrafish Aspergillus infection model. First, Aspergillus spores are isolated and injected into the zebrafish hindbrain ventricle via microinjection. Then, chemical inhibitors such as immunosuppressive drugs are added directly to the larval water. Two methods to monitor the infection in injected larvae are described, including the 1) homogenization of larvae for colony forming unit (CFU) enumeration and 2) a repeated, daily live imaging setup. Overall, these techniques can be used to mechanistically analyze the progression of Aspergillus infection in vivo and can be applied to different host backgrounds and Aspergillus strains to interrogate host-pathogen interactions.

Infection of Zebrafish Larvae with Aspergillus Spores for Analysis of Host-Pathogen Interactions

This protocol describes an Aspergillus infection model in zebrafish larvae. Aspergillus spores are microinjected into the hindbrain of larvae, and chemical treatment is used to induce immunosuppression. Infection progression is monitored via a daily imaging setup to monitor fungal growth and immune responses as well as enumeration of live spores by colony forming unit plating.

斑马鱼幼虫感染 阿斯珀吉卢斯 孢子分析宿主-病原体相互作用

Invasive aspergillosis (IA) is one of&#160;the most common fungal infections among immunocompromised individuals. Despite the availability of antifungal ...

Double Labeling Immunofluorescence using Antibodies from the Same Species to Study Host-Pathogen Interactions

Nowadays, it is possible to find a wide range of molecular tools available to study parasite-host cell interactions. However, some limitations exist to obtain commercial monoclonal or polyclonal antibodies that recognize specific cell structures and proteins in parasites. Besides, there are few commercial antibodies available to label trypanosomatids. Usually, polyclonal antibodies against parasites are prepared in-house and could be more challenging to use in combination with other antibodies produced in the same species. Here, the protocol demonstrates how to use polyclonal and monoclonal antibodies raised in the same species to perform double labeling immunofluorescence to study host cell and pathogen interactions. To achieve the double labeling immunofluorescence, it is crucial to incubate first the mouse polyclonal antibody and then follow the incubation with the secondary mouse IgG antibody conjugated to any fluorochrome. After that, an additional blocking step is necessary to prevent any trace of the primary antibody from being recognized by the next secondary antibody. Then, a mouse monoclonal antibody and its specific IgG subclass secondary antibody conjugated to a different fluorochrome are added to the sample at the appropriate times. Additionally, it is possible to perform triple labeling immunofluorescence using a third antibody raised in a different species. Also, structures such as nuclei and actin can be stained subsequently with their specific compounds or labels. Thus, these approaches presented here can be adjusted for any cell whose sources of primary antibodies are limited.

Here, the protocol describes how to perform double labeling immunofluorescence using primary antibodies raised in the same species to study host-pathogen interactions. Also, it can include the third antibody from a different host in this protocol. This approach can be made in any cell type and pathogens.

使用来自同一物种的抗体进行双标记免疫荧光研究宿主 - 病原体相互作用

Nowadays, it is possible to find a wide range of molecular tools available to study parasite-host cell interactions. However, some limitations exist to ...